Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €23.58 EUR
Change Today -0.237 / -1.00%
Volume 3.8K
EUZ On Other Exchanges
As of 3:35 PM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

eckert & ziegler strahlen un (EUZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/7/14 - €25.95
52 Week Low
01/6/15 - €16.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ECKERT & ZIEGLER STRAHLEN UN (EUZ)

Related News

No related news articles were found.

eckert & ziegler strahlen un (EUZ) Related Businessweek News

No Related Businessweek News Found

eckert & ziegler strahlen un (EUZ) Details

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology for medical, scientific, and industrial use in Europe, North America, Asia/Pacific, and internationally. The company’s Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. This segment also offers custom and one-off design and manufacturing services. Its Radiation Therapy segment develops, manufactures, markets, and sells radioactive products for cancer therapy. This segment’s products and equipment are intended for use by oncologists, radio-therapists, urologists, ophthalmologists, and medical physicists. The company’s Radiopharma segment operates in the field of molecular imaging and nuclear medicine supplying various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment offers products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. Its Others segment engages in the removal, treatment, and conditioning of isotope-related waste materials. The company was founded in 1992 and is headquartered in Berlin, Germany.

700 Employees
Last Reported Date: 05/5/15
Founded in 1992

eckert & ziegler strahlen un (EUZ) Top Compensated Officers

Chairman of The Executive Board, Chief Execut...
Total Annual Compensation: €517.0K
Head of Radiopharma Segment, Member of The Ex...
Total Annual Compensation: €317.0K
Head of Radiation Therapy Segment, Member of ...
Total Annual Compensation: €221.0K
Compensation as of Fiscal Year 2014.

eckert & ziegler strahlen un (EUZ) Key Developments

Eckert & Ziegler Strahlen & Medizintechnik AG Provides Earnings Guidance for the Full Year of 2015

Eckert & Ziegler Strahlen & Medizintechnik AG provided earnings guidance for the full year of 2015. The sale of the shares in OctreoPharm Sciences GmbH to IPSEN took legal effect June 30, 2015 following the receipt of an initial payment. As a result, the Executive Board of the company has raised its profit forecast for 2015 to at least EUR 2.00 per share, or just over EUR 10 million.

Eckert & Ziegler Strahlen and Medizintechnik AG Announces Earnings Results for the First Quarter Ended March 31, 2015

Eckert & Ziegler Strahlen and Medizintechnik AG announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported profit from operations of EUR 3.19 million compared to EUR 3.11 million for the same quarter ended March 31, 2014.

Eckert & Ziegler Announces Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for the Year 2015

Eckert & Ziegler announced earnings results for the first quarter of 2015. For the quarter, the company’s net profit climbed to EUR 2.7 million or EUR 0.51 per share. Sales increased 11% to EUR 34 million, while earnings before interest and tax jumped 60% to EUR 4.8 million. The company predicted it would book sales of EUR 133 million and a net profit in excess of EUR 1.71 per share in the year 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EUZ:GR €23.58 EUR -0.237

EUZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $26.78 USD +0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation EUZ Industry Range
Price/Earnings 16.7x
Price/Sales 1.0x
Price/Book 1.4x
Price/Cash Flow 16.7x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECKERT & ZIEGLER STRAHLEN UN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at